
|Articles|April 22, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
Toxicity of Immunotherapies in Melanoma
Author(s)Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
<<<
Articles in this issue
over 10 years ago
Comparing Two Doses of Ipilimumabover 10 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaover 10 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaover 10 years ago
The Development of T-VEC for Melanomaover 10 years ago
The Role of Macrophages in BRAF Inhibitor Resistance





































